These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1037 related items for PubMed ID: 9024265

  • 1. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 2. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L, Kohlmeier L, Kent K, Marcus R.
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [Abstract] [Full Text] [Related]

  • 3. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM.
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [Abstract] [Full Text] [Related]

  • 4. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
    Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J.
    Calcif Tissue Int; 2008 Aug; 83(2):85-92. PubMed ID: 18626566
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [Abstract] [Full Text] [Related]

  • 6. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.
    Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF.
    J Clin Endocrinol Metab; 2003 Feb; 88(2):569-75. PubMed ID: 12574182
    [Abstract] [Full Text] [Related]

  • 7. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F.
    Lancet; 1997 Aug 23; 350(9077):550-5. PubMed ID: 9284777
    [Abstract] [Full Text] [Related]

  • 8. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.
    Zanchetta JR, Bogado CE, Cisari C, Aslanidis S, Greisen H, Fox J, Lems W.
    Curr Med Res Opin; 2010 Nov 23; 26(11):2627-33. PubMed ID: 20923256
    [Abstract] [Full Text] [Related]

  • 9. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
    Hodsman AB, Fraher LJ.
    Bone Miner; 1990 May 23; 9(2):137-52. PubMed ID: 2161692
    [Abstract] [Full Text] [Related]

  • 10. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun 23; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 11. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 23; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 12. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
    Li Y, Xuan M, Wang B, Yang J, Zhang H, Zhang XZ, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Liu ZM, Li CJ, Wu TF, Sheng ZY, Li PQ, Tong JC.
    Chin Med J (Engl); 2013 Feb 23; 126(3):457-63. PubMed ID: 23422107
    [Abstract] [Full Text] [Related]

  • 13. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study Group.
    Ann Intern Med; 2007 Mar 06; 146(5):326-39. PubMed ID: 17339618
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD.
    J Bone Miner Res; 2000 May 06; 15(5):944-51. PubMed ID: 10804025
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis.
    Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R.
    J Clin Endocrinol Metab; 2003 Nov 06; 88(11):5212-20. PubMed ID: 14602752
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R.
    J Bone Miner Res; 2001 May 06; 16(5):925-31. PubMed ID: 11341338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.